[HTML][HTML] Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
S Mori, F Ogata, R Tsunoda - Clinical Rheumatology - Springer
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
M Shunsuke, O Fumihiko, T Ryusuke - Clinical Rheumatology, 2021 - search.proquest.com
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
S Mori, F Ogata, R Tsunoda - Clinical rheumatology, 2021 - pubmed.ncbi.nlm.nih.gov
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
S Mori, F Ogata, R Tsunoda - Clinical Rheumatology, 2021 - search.ebscohost.com
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
[HTML][HTML] Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
S Mori, F Ogata, R Tsunoda - Clinical Rheumatology, 2021 - ncbi.nlm.nih.gov
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
S Mori, F Ogata, R Tsunoda - Clinical Rheumatology, 2021 - europepmc.org
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
S Mori, F Ogata, R Tsunoda - Clinical Rheumatology, 2021 - europepmc.org
Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …